The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells

Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma

(2012) Z. Li et al.   CLINICAL CANCER RESEARCH

A PP1-binding motif present in BRCA1 plays a role in its DNA repair function

(2012) Young-Mi Yu et al.   International Journal of Biological Sciences

eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206

(2011) Y. Cheng et al.   CANCER RESEARCH

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

Genomic Complexity and AKT Dependence in Serous Ovarian Cancer

(2011) Aphrothiti J. Hanrahan et al.   Cancer Discovery

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells

(2010) Dong-Jun Peng et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer

(2010) Ahmed El-Gazzar et al.   MOLECULAR CANCER THERAPEUTICS

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

The mTOR Inhibitor Rapamycin Suppresses DNA Double-Strand Break Repair

(2010) Honghong Chen et al.   RADIATION RESEARCH

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors

(2008) Craig Lindsley et al.   CURRENT CANCER DRUG TARGETS